AstraZeneca PLC said Monday that its cancer drug Recentin failed in a head to head late stage trial with Roche AG's Avastin in tests for use as an initial treatment against colon cancer. The London-based drug company said it will wait for the results of a second study on ...

Shares of biotechnology company Nektar Therapeutics Inc. jumped Wednesday as analysts brushed off the report of a fourth-quarter loss and focused instead on the company's pipeline of products. The stock rose $1.53, or 12 percent, to $14.06 in afternoon trading. Shares earlier reached a 52-week ...

Pharmaceutical company AstraZeneca PLC said Tuesday that it is reorganizing its global research and development operations and eliminating about 1,800 R&D jobs as part of a previously announced cost-cutting plan. About 550 jobs will be eliminated at AstraZeneca's U ...

Anglo-Swedish drugmaker AstraZeneca on Tuesday said it had agreed to pay the British state 505 million pounds (575 million euros, 786 million dollars) to settle a long-standing tax dispute. By agreeing to resolve claims dating between 1996 and 2010, AstraZeneca said it was able to upgrade its earnings outlook for 2010. "AstraZeneca has increased its 2010 target for core earnings ...